PEG‑MGF is a PEGylated Mechano Growth Factor with a multi‑day half‑life that users take for muscle growth and repair (3 reports, ~67% positive) as well as for anti‑aging or systemic anabolic support (2 reports, 50% positive). Community reports most often cite around 400 µg per day (range 200–400 µg) without a specified schedule or cycling plan, whereas clinician sources advise 200 µg injected subcutaneously each day, also without defined timing or cycle length. The only formal tradeoff noted is that PEG‑MGF lacks an FDA‑approved indication, meaning all human use is off‑label or compounded.
Data last updated
Measured on 3 of 6 axes
Evidence shape
PEG-MGF sits in the evidence tier 'none', with zero human published studies, an empty human‑published‑study indications list, zero registered trials, and zero indications mapped. Depth shows 0 trials (no further depth detail), breadth shows 0 indications (no further breadth detail), and quality notes no completed trials (no further quality detail), while all indication arrays—populated, thin, animal‑only, and no‑data—are empty. Consequently, there is no clinical data to support any efficacy or safety claim, and no trial outcomes have been posted.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
No animal or in-vitro support rows have been captured yet.
Published literature
The research corpus was searched; no standalone peptide-level publications were indexed beyond the trials and preclinical rows above.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column · 13 out-of-stock offers not shown
How PEG-MGF is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
Based on a single source, clinicians typically administer 200 mcg of PEG‑MGF subcutaneously each day, and no specific cycling regimen is reported.
Community reports show PEG‑MGF doses between 200 mcg and 400 mcg; one user takes 200 mcg twice daily, while two others report a single 400 mcg dose (frequency not specified).